BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29359992)

  • 1. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
    Zhang D; Whitaker B; Derebe MG; Chiu ML
    MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
    Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
    Richards JO; Karki S; Lazar GA; Chen H; Dang W; Desjarlais JR
    Mol Cancer Ther; 2008 Aug; 7(8):2517-27. PubMed ID: 18723496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
    Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
    Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor.
    Hunter S; Indik ZK; Kim MK; Cauley MD; Park JG; Schreiber AD
    Blood; 1998 Mar; 91(5):1762-8. PubMed ID: 9473244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.
    Suzuki M; Yamanoi A; Machino Y; Ootsubo M; Izawa K; Kohroki J; Masuho Y
    J Biochem; 2016 Jan; 159(1):67-76. PubMed ID: 26254483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.
    Yang Y; Chai X; Xin W; Wang D; Dai C; Qian F; Yang T
    FEBS Lett; 2021 Jun; 595(11):1587-1603. PubMed ID: 33792041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
    Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
    Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.
    Nagashima H; Ootsubo M; Fukazawa M; Motoi S; Konakahara S; Masuho Y
    J Biosci Bioeng; 2011 Apr; 111(4):391-6. PubMed ID: 21215693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.